Rosetta Genomics Analysis
Rosetta Genomics has over 2.45 Million in debt which may indicate that it relies heavily on debt financing. Rosetta Genomics' financial risk is the risk to Rosetta Genomics stockholders that is caused by an increase in debt.
Asset vs Debt
Equity vs Debt
Rosetta Genomics' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Rosetta Genomics' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Rosetta Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Rosetta Genomics' stakeholders.
For most companies, including Rosetta Genomics, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Rosetta Genomics, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Rosetta Genomics' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that Rosetta Genomics' debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Rosetta Genomics is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Rosetta Genomics to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Rosetta Genomics is said to be less leveraged. If creditors hold a majority of Rosetta Genomics' assets, the Company is said to be highly leveraged.
Rosetta Genomics is undervalued with Real Value of 0.0 and Hype Value of 0.0. The main objective of Rosetta Genomics delisted stock analysis is to determine its intrinsic value, which is an estimate of what Rosetta Genomics is worth, separate from its market price. There are two main types of Rosetta Genomics' stock analysis: fundamental analysis and technical analysis.
The Rosetta Genomics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Rosetta Genomics' ongoing operational relationships across important fundamental and technical indicators.
Rosetta |
Rosetta Stock Analysis Notes
About 14.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.01. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Rosetta Genomics recorded a loss per share of 6.41. The entity had not issued any dividends in recent years. The firm had 1:15 split on the 17th of March 2017. Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. Rosetta Genomics Ltd. was founded in 2000 and is headquartered in Rehovot, Israel. Rosetta Genomics operates under Diagnostics Research classification in USA and traded on Nasdaq Capital Markets. It employs 86 people. To find out more about Rosetta Genomics contact the company at 972 73 222 0700 or learn more at http://www.rosettagx.com.Rosetta Genomics Investment Alerts
| Rosetta Genomics is not yet fully synchronised with the market data | |
| Rosetta Genomics has some characteristics of a very speculative penny stock | |
| Rosetta Genomics has a very high chance of going through financial distress in the upcoming years | |
| Rosetta Genomics has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations | |
| The company reported the previous year's revenue of 2.86 M. Net Loss for the year was (9.48 M) with profit before overhead, payroll, taxes, and interest of 498 K. | |
| Rosetta Genomics currently holds about 1.32 M in cash with (11.68 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.51. |
Rosetta Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.07 M.Rosetta Genomics Outstanding Bonds
Rosetta Genomics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Rosetta Genomics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Rosetta bonds can be classified according to their maturity, which is the date when Rosetta Genomics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Rosetta Genomics Debt to Cash Allocation
Many companies such as Rosetta Genomics, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
Rosetta Genomics currently holds 2.45 M in liabilities with Debt to Equity (D/E) ratio of 222.8, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Rosetta Genomics has a current ratio of 2.05, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Rosetta Genomics' use of debt, we should always consider it together with its cash and equity.Rosetta Genomics Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Rosetta Genomics' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Rosetta Genomics, which in turn will lower the firm's financial flexibility.Rosetta Genomics Corporate Bonds Issued
Most Rosetta bonds can be classified according to their maturity, which is the date when Rosetta Genomics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Rosetta Genomics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Global Correlations Now
Global CorrelationsFind global opportunities by holding instruments from different markets |
| All Next | Launch Module |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Other Consideration for investing in Rosetta Stock
If you are still planning to invest in Rosetta Genomics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Rosetta Genomics' history and understand the potential risks before investing.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |